346 related articles for article (PubMed ID: 38004437)
1. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM; C Courtes A; Jones G; Soares JC; Machado-Vieira R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004437
[TBL] [Abstract][Full Text] [Related]
2. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Cook J; Halaris A
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110603. PubMed ID: 35842074
[TBL] [Abstract][Full Text] [Related]
4. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
Vasiliu O
Front Pharmacol; 2022; 13():884155. PubMed ID: 35847011
[TBL] [Abstract][Full Text] [Related]
5. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
6. Novel antidepressant drugs: Beyond monoamine targets.
Gonda X; Dome P; Neill JC; Tarazi FI
CNS Spectr; 2023 Feb; 28(1):6-15. PubMed ID: 34588093
[TBL] [Abstract][Full Text] [Related]
7. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Jha MK; Mathew SJ
Am J Psychiatry; 2023 Mar; 180(3):190-199. PubMed ID: 36855876
[TBL] [Abstract][Full Text] [Related]
9. GABA
Luscher B; Maguire JL; Rudolph U; Sibille E
Trends Pharmacol Sci; 2023 Sep; 44(9):586-600. PubMed ID: 37543478
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
[TBL] [Abstract][Full Text] [Related]
11. Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence.
Parincu Z; Iosifescu DV
Expert Rev Neurother; 2023 Mar; 23(3):205-212. PubMed ID: 36943010
[TBL] [Abstract][Full Text] [Related]
12. Role of Ketamine in the Treatment of Psychiatric Disorders.
Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
[TBL] [Abstract][Full Text] [Related]
13. Keeping up with the clinical advances: depression.
Ragguett RM; Tamura JK; McIntyre RS
CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
[TBL] [Abstract][Full Text] [Related]
14. [GABAergic approach of postpartum depression: A translational review of literature].
Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
[TBL] [Abstract][Full Text] [Related]
15. Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Chaki S; Watanabe M
Neuropharmacology; 2023 Feb; 223():109348. PubMed ID: 36423706
[TBL] [Abstract][Full Text] [Related]
16. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH
World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
18. The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Halaris A; Cook J
Adv Exp Med Biol; 2023; 1411():487-512. PubMed ID: 36949323
[TBL] [Abstract][Full Text] [Related]
19. Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.
Réus GZ; de Moura AB; Borba LA; Abelaira HM; Quevedo J
Mol Neuropsychiatry; 2019 Oct; 5(4):178-189. PubMed ID: 31768371
[TBL] [Abstract][Full Text] [Related]
20. Esketamine for treatment‑resistant depression: A review of clinical evidence (Review).
Vasiliu O
Exp Ther Med; 2023 Mar; 25(3):111. PubMed ID: 36793329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
